Zeltia shares surge on positive late-stage cancer data

Shares of Spain's Zeltia shot up on the news that it has positive late-stage data for the ovarian cancer drug Yondelis to support its application for marketing approval. The developer plans to file in the U.S. and Europe in the last quarter of the year. Researchers for the company say that the data demonstrates that a combination of Yondelis and Doxil was significantly better than Doxil alone in halting tumor growth.

- read the report from The Guardian

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.